Overview

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Status:
Not yet recruiting
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Phase:
Phase 3
Details
Lead Sponsor:
KalVista Pharmaceuticals, Ltd.